Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
Volume 0.47M
Average 0.09M
GYRE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Gyre Therapeutics, Inc.NASDAQ: GYRE
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow shrinks to $0
Q1 FY2026 stock-based compensation was $0, compared with $507K a year earlier. Trailing-twelve-month stock-based compensation was $6.65M. Over 3 fiscal years it compounded at -18.8% a year.
Context
- Stock-based compensation amounted to 6.1% of revenue in FY2025, up 5.4 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.66M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 7.16M USD
- Year-over-year change
- +761.3%
- 4-year CAGR
- +20.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.16M | +761.3% |
| FY2024 | 2024-12-31 | 831K | -88.6% |
| FY2023 | 2023-12-31 | 7.28M | -45.5% |
| FY2022 | 2022-12-31 | 13.37M | +292.5% |
| FY2021 | 2021-12-31 | 3.41M | — |
Stock-Based Compensation vs competitors
How GYRE compares with its peers on the latest reported figures
- GYRE's LTM Mar 2026 stock-based compensation of $6.65M is the 2nd largest of the 4 companies compared; the peer median is $5.11M.
- Its year-over-year change of +519.2% is the highest of 4, against a peer median of -18.8%.
- Stock-based compensation amounts to 5.7% of revenue for GYRE, versus a peer median of 68.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.58M | -41.5% | +5.1% | — | |
| LTM Mar 2026 | $6.65M | +519.2% | -18.8% | 5.7% | |
| LTM Mar 2026 | $5.11M | +30.3% | -5.3% | 68.1% | |
| LTM Mar 2026 | $1.88M | -18.8% | -16.7% | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding GYRE) | $5.11M | -18.8% | -5.3% | 68.1% | |
Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.93M) | 4.31M | (85.48M) | 17.9M | 9.88M |
| Depreciation & Amortization | 290K | 1.13M | 1.11M | 1.59M | 2.48M |
| Deferred Income Tax | (3.89M) | (838K) | (1.16M) | (1M) | (1.11M) |
| Stock-Based Compensation | 3.41M | 13.37M | 7.28M | 831K | 7.16M |
| Change in Working Capital | 483K | (7.8M) | 7.46M | (15.69M) | (15.55M) |
| Accounts Receivables | 1.5M | (7.92M) | 1.3M | (9.29M) | (11.95M) |
| Inventory | 3.88M | (879K) | 1.75M | (2.14M) | (3.63M) |
| Accounts Payables | 500K | (112K) | 192K | (245K) | 13K |
| Other Working Capital | (5.39M) | 1.11M | 4.22M | (4.02M) | 17K |
| Other Non-Cash Items | 3.89M | 503K | 96.68M | (7.27M) | (1.85M) |
| Operating Cash Flow | (83.76M) | 10.68M | 25.89M | (3.64M) | 1.01M |
| Capital Expenditures | (839K) | (5M) | (8.59M) | (3.13M) | (1.19M) |
| Acquisitions (Net) | 0 | (1.33M) | 4.02M | (1.69M) | 30K |
| Purchases of Investments | 0 | (7.48M) | (15.74M) | (15.47M) | 0 |
| Sales of Investments | 49.03M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (13K) | 471K | (412K) | 686K |
| Investing Cash Flow | 48.19M | (13.81M) | (19.76M) | (19.88M) | (474K) |
| Debt Repayment | (6.7M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 49.55M | 0 | 0 | 773K | 25.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.7M | 0 | 0 | 1.33M | (1.49M) |
| Financing Cash Flow | 49.55M | 0 | 2.5M | 2.1M | 24.38M |
| Effect of Forex Changes | 0 | (1.89M) | (298K) | (273K) | 343K |
| Net Change in Cash | 13.99M | (5.03M) | 8.33M | (21.7M) | 25.26M |
| Free Cash Flow | (84.59M) | 5.68M | 17.31M | (6.77M) | (180K) |
Gyre Therapeutics, Inc.
NASDAQ:GYRE
Intrinsic Alpha fair value
Locked
Current Price
$4.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.